Varicella Seroprevalence in the U.S.: Data from the National Health and Nutrition Examination Survey, 1999-2004
Overview
Affiliations
Objective: We estimated the varicella seroprevalence among the U.S. population aged 6-49 years based on retested National Health and Nutrition Examination Survey (NHANES) specimens collected between 1999 and 2004--originally tested using a method unsuitable for detecting vaccine-induced immunity--and compared it with historical estimates.
Methods: We performed a confirmatory test suitable for detecting vaccine-induced immunity on all available specimens from 6- to 19-year-olds who originally tested negative (n = 633), and on 297 randomly selected specimens that had tested positive. Retest results superseded original results for determining seroprevalence. We assessed seroprevalence for the entire sample aged 6-49 years (n = 16,050) by participant demographic characteristics and compared it with historical estimates (NHANES 1988-1994).
Results: The percentage of false-negative results for the original test was higher for specimens from younger children (6-11 years of age: 27.5%; 12-19 years of age: 13.3%) and for specimens collected most recently (2001-2004: 26.0%; 1999-2000: 12.6%). The age-adjusted rate of varicella seroprevalence for 1999-2004 was 93.6% for 6- to 19-year-olds and 98.0% for adults aged 20-49 years compared with 90.0% and 98.1%, respectively, for 1988-1994. We found an increase in seropositivity between the survey periods, from 93.2% to 97.2% (p < 0.001) among 12- to 19-year-olds. For children, non-Hispanic black ethnicity and younger age were associated with lower seroprevalence in both survey periods.
Conclusions: Varicella seroprevalence increased with age among children and was uniformly high in the U.S. adult population between 1999 and 2004. The original testing produced false-negative seroprevalence results among children's specimens collected between 1999 and 2004 from 6- to 19-year-olds.
Computational design of prefusion-stabilized Herpesvirus gB trimers.
McCallum M, Veesler D bioRxiv. 2024; .
PMID: 39484573 PMC: 11526958. DOI: 10.1101/2024.10.23.619923.
Herpes zoster and long-term risk of subjective cognitive decline.
Yeh T, Curhan G, Yawn B, Willett W, Curhan S Alzheimers Res Ther. 2024; 16(1):180.
PMID: 39138535 PMC: 11323373. DOI: 10.1186/s13195-024-01511-x.
Alhwayan A, Alsallal A, Njadat M, Alhammad M, Haddadin B Cureus. 2024; 16(6):e63515.
PMID: 39081426 PMC: 11288336. DOI: 10.7759/cureus.63515.
McNaughton A, Karsenti N, Kwan J, Adawi A, Mansuri S, Boggild A Infect Dis Rep. 2024; 16(4):628-637.
PMID: 39051248 PMC: 11270367. DOI: 10.3390/idr16040048.
Contribution of CNS and extra-CNS infections to neurodegeneration: a narrative review.
Kettunen P, Koistinaho J, Rolova T J Neuroinflammation. 2024; 21(1):152.
PMID: 38845026 PMC: 11157808. DOI: 10.1186/s12974-024-03139-y.